(Q54280595)

English

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

1 reference

based on heuristic

inferred from title

author name string

S Morecki

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

S Revel-Vilk

2

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

C Nabet

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

M Pick

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

A Ackerstein

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

A Nagler

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

E Naparstek

7

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

M Ben Shahar

8

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

S Slavin

9

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

publication date

1 January 1992

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

35

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

401-411

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of NK cell activity against fresh human leukemia in culture with interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biology and clinical relevance of human natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of cancer using interleukin 2: current status and future prospects

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Non-Hodgkin's lymphoma: natural cell-mediated cytotoxicity correlated with histological classification and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Separation of leukocytes from blood and bone marrow. Introduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia. I. Analysis of the defect using the monoclonal antibodies HNK-1 (LEU-7) and B73.1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct antiproliferative effects of recombinant human interferon-alpha B/D hybrids on human tumor cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged defects of interleukin-2 production, responsiveness, and receptor expression in patients with acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Normal hematopoietic progenitor cells and malignant lymphohematopoietic cells show different susceptibility to direct cell-mediated MHC-non-restricted lysis by T cell receptor-/CD3-, T cell receptor gamma delta+/CD3+ and T cell receptor-alpha beta+/

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon therapy for lymphoproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

'Nonspecific' MHC-unrestricted killer cells and their receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 and alpha interferon induced in vitro modulation of spontaneous cell mediated cytotoxicity in patients with cancer of the uterine cervix undergoing radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer cells: their roles in defenses against disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A recycling defect as a characteristic of natural killer cells in childhood acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural and antibody-dependent cellular cytotoxicity in chronic myeloid leukemia patients in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2: inception, impact, and implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1394343

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01789019

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/1394343

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54280595&oldid=2212408197"